26
Participants
Start Date
July 31, 2006
Primary Completion Date
March 31, 2009
Study Completion Date
August 31, 2009
Sagopilone (BAY86-5302, ZK 219477)
Phase 1: dose escalation/deescalation, starting dose 12mg/m² Sagopilone, Phase 2: MTD or RPIID
Cisplatin
75 mg/m² as a 1 h infusion after the sagopilone infusion on Day 1
Berlin
Hamburg
Essen
Mainz
Wiesbaden
Frankfurt am Main
Gerlingen
Löwenstein
München
München
Lead Sponsor
Bayer
INDUSTRY